Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by HABP2 is an extracellular serine protease that binds hyaluronic acid and is involved in cell adhesion. Additionally we are shipping HABP2 Proteins (17) and HABP2 Kits (7) and many more products for this protein.
Showing 10 out of 40 products:
Human Monoclonal HABP2 Primary Antibody for IP, ELISA - ABIN516334
Altmäe, Kallak, Fridén, Stavreus-Evers: Variation in hyaluronan-binding protein 2 (HABP2) promoter region is associated with unexplained female infertility. in Reproductive sciences (Thousand Oaks, Calif.) 2011
Show all 2 Pubmed References
Human Polyclonal HABP2 Primary Antibody for IHC, IHC (p) - ABIN4316533
Bachmann, Burté, Pramana, Conte, Brown, Orimadegun, Ajetunmobi, Afolabi, Akinkunmi, Omokhodion, Akinbami, Shokunbi, Kampf, Pawitan, Uhlén, Sodeinde, Schwenk, Wahlgren, Fernandez-Reyes, Nilsson: Affinity proteomics reveals elevated muscle proteins in plasma of children with cerebral malaria. in PLoS pathogens 2014
Letter: G534E variant in HABP2 is not associated with non-medullary thyroid cancer in the Spanish population.
Study showed that lower FSAP antigen plasma levels were associated with a higher chance of arterial recanalization after tissue plasminogen activator (show PLAT Antibodies) treatment, suggesting an involvement of FSAP in tissue plasminogen activator (show PLAT Antibodies)-induced clot (show TXNDC17 Antibodies) lysis. FSAP antigen determination might be useful in predicting tissue plasminogen activator (show PLAT Antibodies) response in stroke patients.
HABP2 polymorphisms are not associated with thyroid cancer.
the promoter activity, which could phenocopy changes in Habp2 mRNA in response to TGF-beta (show TGFB1 Antibodies), was found to be located in the 177-bp region upstream of the transcription start site, and this region did not contain any SMAD (show SMAD1 Antibodies) binding sites.
Results show that G534E germline variant in HABP2 does not account for the familial nature of nonmedullary thyroid cancer in Australian kindreds but and is common in the general population.
omology modeling suggested that the Glu (show DCTN1 Antibodies)-221 side chain could sterically hinder insertion of the N terminus into the HABP2 protease domain, helping to explain the detrimental effects of Glu (show DCTN1 Antibodies)-221 substitution on HABP2 activity.
The data do not support the pathogenicity of the HABP2 c.1601G > A variant but highlight the existence of a new one that should be more extensively searched for in familial papillary thyroid carcinoma patients and its pathogenicity more carefully evaluated.
No evidence supporting a role for the HABP2 G534E variant (SNP rs7080536) in papillary thyroid carcinoma.
HABP2 G534E appears to be a susceptibility gene in a subgroup of Familial Non-Medullary Thyroid Cancer (FNMTC), providing important diagnostic implications for this hereditary thyroid cancer.
HABP2, which encodes an extracellular serine protease involved in coagulation, fibrinolysis, and inflammatory pathways, may be a genetic susceptibility locus for early-onset stroke. [Meta-Analysis]
FSAP deficiency causes an increase in CCL2 (show CCL2 Antibodies) expression and CCL2 (show CCL2 Antibodies)-mediated infiltration of leukocytes into the injured vessel
Lack of endogenous FSAP impaired the formation of stable, occlusive thrombi in mice.
Results show that the lack of FSAP in mice worsens the outcome of stroke; in the absence of FSAP there was a stronger inflammatory response and lower cell survival due to insufficient activation of the PI3K/AKT (show AKT1 Antibodies) pathway
Lower FSAP expression is associated with enhanced liver fibrosis and inflammation in patients with chronic hepatic disorders and murine experimental liver injury.
Data indicate that FSAP mediates proteolytic cleavage and activation of bone morphogenetic protein-2 (BMP-2 (show BMP2 Antibodies)).
Hyaluronic acid binding protein 2 (HABP2) negatively regulates vascular integrity via activation of protease-activated receptor/RhoA (show RHOA Antibodies)/Rho kinase (show ROCK2 Antibodies) signaling. It represents a potential therapeutic target for syndromes of increased vascular permeability.
The protein encoded by this gene is an extracellular serine protease that binds hyaluronic acid and is involved in cell adhesion. The encoded protein is synthesized as a single chain, but then undergoes an autoproteolytic event to form the functional heterodimer. Further autoproteolysis leads to smaller, inactive peptides. This protease is known to cleave urinary plasminogen activator, coagulation factor VII, and the alpha and beta chains of fibrinogen, but not prothrombin, plasminogen, or the gamma chain of fibrinogen. Two transcript variants encoding different isoforms have been found for this gene.
hyaluronan binding protein 2
, hyaluronan-binding protein 2-like
, factor VII activating protein
, factor VII-activating protease
, factor seven-activating protease
, hepatocyte growth factor activator-like protein
, hyaluronan-binding protein 2
, hyaluronic acid binding protein 2
, plasma hyaluronan binding protein
, plasma hyaluronan-binding protein
, hyaduronic acid-binding protein 2